SANUWAVE Health Projects Q2 Revenue Decline to $8.5M-$9.5M
Summary
SANUWAVE Health has provided Q2 revenue guidance, projecting sales between $8.5 million and $9.5 million. This guidance indicates a sequential decline compared to Q1 2026, which had revenue guidance of $9.6 million to $10.3 million. While the company recently reported a significant reduction in net loss and positive operating cash flow for Q1, this lower revenue outlook for Q2 could raise concerns about its near-term growth trajectory.
At the time of this announcement, SNWV was trading at $13.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $126.1M. The 52-week trading range was $14.11 to $46.59. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.